Literature DB >> 2067315

Similar frequency of autoantibodies against pneumocytes type II and Clara cells in patients with interstitial lung diseases and healthy persons.

R Erlinger1, G Rauh, J Behr, U Schumacher, U Welsch, N Zöllner.   

Abstract

Several experimental findings suggest an association between interstitial lung diseases and autoantibodies. Antibodies against lung tissue including pneumocytes type II in patients suffering from idiopathic pulmonary fibrosis (IPF) were reported in recent years. In this investigation the serum of 103 persons (10 with IPF, 23 with M. Boeck, 18 with rheumatoid arthritis (RA) and 52 healthy controls) was examined for autoantibodies against pneumocytes type II and Clara cells by indirect immunofluorescence on human lung tissue. These antibodies against both cell types are an additional proof for common antigens in pneumocytes type II and Clara cells. The autoantibodies were present in similar frequency in the 4 groups (IPF: 20%, M. Boeck: 26.1%, RA: 22.2% and 23.1% of the healthy controls). So no significant association was found between the antibodies and the interstitial lung diseases. A role of the antibodies in the pathogenesis of the diseases, however, can not be excluded by this study. A possible role as parameter of development of interstitial lung diseases should be subject to further investigations in form of a prospective follow up study.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2067315     DOI: 10.1007/BF01644760

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  21 in total

1.  Idiopathic pulmonary fibrosis: cellular and molecular pathogenesis.

Authors:  J C Weissler
Journal:  Am J Med Sci       Date:  1989-02       Impact factor: 2.378

2.  Immunocytochemical localization of the major surfactant apoproteins in type II cells, Clara cells, and alveolar macrophages of rat lung.

Authors:  S R Walker; M C Williams; B Benson
Journal:  J Histochem Cytochem       Date:  1986-09       Impact factor: 2.479

3.  An immunologic study of the apoproteins of rat lung surfactant.

Authors:  S L Katyal; G Singh
Journal:  Lab Invest       Date:  1979-05       Impact factor: 5.662

4.  Antibodies in some chronic fibrosing lung diseases. II. Immunofluorescent studies.

Authors:  M Turner-Warwick; P Haslam; J Weeks
Journal:  Clin Allergy       Date:  1971-06

5.  Evaluation of some immunological parameters in interstitial lung disease by discriminant analysis.

Authors:  G Bertorelli; A Pesci; G F Consigli; R Minisini; P A Mori; P P Dall'Aglio; D Olivieri
Journal:  Respiration       Date:  1988       Impact factor: 3.580

Review 6.  Cells of the lung: biology and clinical implications.

Authors:  D B Gail; C J Lenfant
Journal:  Am Rev Respir Dis       Date:  1983-03

7.  Pulmonary damage induced in mice by a monoclonal antibody to proteins associated with pig pulmonary surfactant.

Authors:  Y Fujita; K Kogishi; Y Suzuki
Journal:  Exp Lung Res       Date:  1988       Impact factor: 2.459

Review 8.  Bronchoalveolar lavage.

Authors:  H Y Reynolds
Journal:  Am Rev Respir Dis       Date:  1987-01

Review 9.  Idiopathic fibrosing alveolitis: a review with emphasis on ultrastructural and immunohistochemical features.

Authors:  S P Hammar; R H Winterbauer; D Bockus; F Remington; S Friedman
Journal:  Ultrastruct Pathol       Date:  1985       Impact factor: 1.094

10.  Monoclonal antibodies to surfactant proteins SP28-36 label canine type II and nonciliated bronchiolar cells by immunofluorescence.

Authors:  M C Williams; S Hawgood; D B Schenk; J Lewicki; M N Phelps; B Benson
Journal:  Am Rev Respir Dis       Date:  1988-02
View more
  2 in total

1.  Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis.

Authors:  W A Wallace; S N Roberts; H Caldwell; E Thornton; A P Greening; D Lamb; S E Howie
Journal:  Thorax       Date:  1994-03       Impact factor: 9.139

2.  Idiopathic pulmonary fibrosis is associated with circulating antiepithelial antibodies.

Authors:  Ahmed Fahim; Mei C Chong; Michael G Crooks; Simon P Hart
Journal:  Lung       Date:  2012-05-16       Impact factor: 2.584

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.